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Natural killer (NK) cells contribute to innate 
immune responses by killing virus-infected or 
malignantly transformed cells and by producing 
cytokines such as IFN- and TNF. NK cell acti-
vation is determined by a balance of signals from 
inhibitory and activating receptors. Because   
ligands of inhibitory receptors include MHC 
class I and class I–-like molecules, the absence 
of self-MHC expression leads to NK activa-
tion  (Cerwenka  and  Lanier,  2001). Approxi-
mately 20 receptors contribute to NK activation 
(Cerwenka  and  Lanier,  2001; Vivier  et  al.,   
2008). When ligands for activating receptors are 
sufficiently abundant, activating signals overcome 
inhibitory signals.
There are two currently accepted models 
for in vivo NK activation. One is that NK cells 
usually circulate in a naive state and are acti-
vated through interaction directly with ligands 
for pattern recognition receptors (PRRs) ex-
pressed by NK cells or interaction with cells 
that express PRR ligands (Hornung et al., 2002; 
Sivori et al., 2004). When pathogens enter the 
host,  innate  immune  sensors,  such  as Toll- 
like receptors (TLRs), RIG-I-like receptors, 
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In myeloid dendritic cells (mDCs), TLR3 is expressed in the endosomal membrane and inter-
acts with the adaptor toll/interleukin 1 receptor homology domain–containing adaptor 
molecule 1 (TICAM-1; TRIF). TICAM-1 signals culminate in interferon (IFN) regulatory 
factor (IRF) 3 activation. Co-culture of mDC pretreated with the TLR3 ligand polyI:C and 
natural killer (NK) cells resulted in NK cell activation. This activation was triggered by cell-
to-cell contact but not cytokines. Using expression profiling and gain/loss-of-function 
analyses of mDC genes, we tried to identify a TICAM-1–inducing membrane protein that 
participates in mDC-mediated NK activation. Of the nine candidates screened, one contained 
a tetraspanin-like sequence and satisfied the screening criteria. The protein, referred to as 
IRF-3–dependent NK-activating molecule (INAM), functioned in both the mDC and NK cell 
to facilitate NK activation. In the mDC, TICAM-1, IFN promoter stimulator 1, and IRF-3, but 
not IRF-7, were required for mDC-mediated NK activation. INAM was minimally expressed 
on NK cells, was up-regulated in response to polyI:C, and contributed to mDC–NK reciprocal 
activation via its cytoplasmic tail, which was crucial for the activation signal in NK cells. 
Adoptive transfer of INAM-expressing mDCs into mice implanted with NK-sensitive tumors 
caused NK-mediated tumor regression. We identify a new pathway for mDC–NK contact-
mediated NK activation that is governed by a TLR signal-derived membrane molecule.
© 2010 Ebihara et al.  This article is distributed under the terms of an Attribution–
Noncommercial–Share Alike–No Mirror Sites license for the first six months after 
the publication date (see http://www.rupress.org/terms). After six months it is 
available under a Creative Commons License (Attribution–Noncommercial–Share 
Alike 3.0 Unported license, as described at http://creativecommons.org/licenses/
by-nc-sa/3.0/).
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in our laboratory as a low H-2 expressor (Mukai et al., 1999), 
was used as an NK target. PolyI:C, WT BMDC, and NK cells 
were all found to be essential for NK-mediated B16D8 cyto-
lysis in the in vitro assay (Fig. 1 A). PolyI:C-mediated NK ac-
tivation was at baseline levels in a transwell with a 0.4-µm 
pore, suggesting the importance of direct BMDC-NK con-
tact for this cytolysis induction (Fig. 1 A). When WT BMDCs 
were replaced with TICAM-1/ BMDCs in this system, 
polyI:C-mediated NK activation was partly abolished (Fig. 1 B; 
and Fig. S1, A and B). TICAM-1 of BMDC was involved in 
driving NK activation, and ultimately B16D8 cells were dam-
aged by BMDC-derived NK cells (Fig. 1 B). PolyI:C-mediated 
NK activation occurred even when WT NK cells were re-
placed with TICAM-1/ NK cells (Fig. 1 B), which means 
that NK activation barely depends on the TICAM-1 pathway 
in NK cells.
PolyI:C-activated splenic NK cells were i.p. injected into   
B6 mice to kill B16D8 cells ex vivo, which is consistent with 
previous studies (McCartney et al., 2009; Miyake et al., 2009), 
and this polyI:C-mediated NK activation was markedly reduced 
in IPS-1/ mice established in our laboratory (Fig. S1 C), sug-
gesting that NK cell activation is induced via not only the   
TICAM-1 pathway but also the IPS-1 pathway, which was 
largely comparable with previous studies (McCartney et al., 
2009; Miyake et al., 2009). IPS-1 in BMDC was more involved 
in polyI:C-driven NK cytotoxicity than TICAM-1 but almost 
equally contributed to NK-dependent IFN- induction to   
TICAM-1 in our setting (Fig. S1 B). In addition, the serum 
level of IL-12p40 in polyI:C-treated mice was largely depen-
dent on TICAM-1 (Fig. S1 D; Kato et al., 2006; Akazawa et al., 
2007a). In the supernatant of polyI:C-stimulated BMDC and 
the serum samples from polyI:C-treated mice, IL-12p70 was 
not detected by ELISA (unpublished data). These results suggest 
that polyI:C activates NK cells largely secondary to mDC matu-
ration, which is sustained by the IPS-1 or TICAM-1 pathway   
of mDC. Even though NK cells express TLR3, they are only 
minimally activated by polyI:C alone. Signaling by TICAM-1 
in BMDC can augment NK cytotoxicity and IFN- production 
via BMDC/NK contact.
The TICAM-1 pathway activates the transcription factor 
IRF-3. More precisely, exogenous addition of polyI:C can   
activate endosomal TLR3 and cytoplasmic RIG-I/MDA5.   
RIG-I/MDA5 assembles the adaptor IPS-1, which in turn re-
cruits the NAP1–IKK-–TBK1 kinase complex and activates 
both IRF-3 and IRF-7 (Fitzgerald et al., 2003;  Yoneyama et al., 
2004). For this reason, we examined the role of IRF-3 and 
IRF-7 in BMDC for activation of NK cells by polyI:C. Activa-
tion of IRF-3, but not IRF-7, was required for BMDC to in-
duce NK cytotoxicity (Fig. 1 C). IL-2 (Zanoni et al., 2005), 
IFN- (Gerosa et al., 2002), and trans-presenting IL-15 (Lucas 
et al., 2007) induced by BMDC are reported to be key cyto-
kines for BMDC-mediated NK activation in response to   
polyI:C. However, even with normal levels of IFN- production 
and IL-15 expression (Fig. 1, D and E), TICAM-1/ BMDCs 
failed to induce full NK cytotoxicity (Fig. 1 B). In contrast, 
IRF-7/ BMDCs, which have impaired IFN- and IL-15 
NOD-like receptors, and lectin family proteins, which are PRRs, 
recognize a variety of microbial patterns (pathogen-associated 
molecular patterns [PAMPs]; Medzhitov and Janeway, 1997). 
Mouse NK cells express almost all TLRs (TLR1–3, 4, and 6–9), 
and some of these are directly activated by pathogens with   
the help of IL-12, IL-18, IFN-, and other cytokines (Newman 
and Riley, 2007). The other is that naive NK cells tend to be 
recruited to the draining LNs, where they are primed to be 
effectors with the help of mature myeloid DCs (mDC) and 
released into peripheral tissues (Fernandez et al., 1999). In this 
case,  mDCs  provide  direct  activating  signals  to  NK  cells 
through cell–cell contact (Gerosa et al., 2002; Akazawa et al., 
2007a; Lucas et al., 2007). mDCs also produce proinflamma-
tory cytokines and IFN- after recognizing PAMPs (Newman 
and Riley, 2007). In this mDC-mediated NK activation, how-
ever, the molecules and mechanisms in mDC that are dedi-
cated to NK activation in vivo remain to be understood.
In this study, we focused on the molecules that are induced 
in mDC during maturation by exposure to double-stranded (ds) 
RNA and the molecules involved in priming NK cells for target 
killing (Akazawa et al., 2007a). dsRNA of viral origin and the 
synthetic analogue polyI:C induce NK activation in concert 
with mDC in vivo and in vitro (Seya and Matsumoto, 2009). 
PolyI:C is recognized by the cytoplasmic proteins RIG-I/MDA5 
and the membrane protein TLR3, both of which are expressed 
in mDC (Matsumoto and Seya, 2008). Although RIG-I and 
MDA5 in the cytoplasm deliver a signal to the adaptor protein 
IFN promoter stimulator 1 (IPS-1; also known as MAVS, VISA, 
and Cardif) on the outer membrane of the mitochondria (Kawai 
et al., 2005; Meylan et al., 2005; Seth et al., 2005; Xu et al., 2005), 
TLR3 in the endosomal membrane recruits the adaptor protein 
toll/IL-1 receptor homology domain–containing adaptor mole-
cule 1 (TICAM-1)/TRIF (Oshiumi et al., 2003a; Yamamoto   
et al., 2003a). Both adaptor proteins activate TBK1 and/or IB 
kinase  (IKK)  ,  which  phosphorylate  IFN  regulatory  factor 
(IRF) 3 and IRF-7 to induce type I IFN (Sasai et al., 2006).   
We previously showed that the TLR3–TICAM-1 pathway in 
mDC participates in inducing anti-tumor NK cytotoxicity by 
polyI:C (Akazawa et al., 2007a). mDC matured with polyI:C can 
enhance NK cytotoxicity through mDC-NK cell–cell contact 
(Akazawa et al., 2007a). Therefore, we hypothesized that an un-
identified protein is up-regulated on the cell surface of mDC 
through activation of the TLR3–TICAM-1 pathway, and this 
protein enables mDC to interact with and activate NK cells.   
This is the first study identifying an IRF-3–dependent NK- 
activating molecule, which we abbreviated INAM. INAM is a 
TICAM-1–inducible molecule on the cell surface of BM- 
derived DCs (BMDCs) that activates NK cells via cell–cell con-
tact. Our data imply that mDCs harbor a pathway for driving 
NK activation that acts in conjunction with dsRNA and TLR3.
RESULTS
TICAM-1/IRF-3 signal in BMDCs augments NK activation
An  in  vitro  system  for  evaluating  NK  activation  through 
BMDC-NK contact was established for this study (Fig. 1 A). 
A mouse melanoma cell subline B16D8, which was established JEM VOL. 207, November 22, 2010 
Article
2677
from other tetraspanins like CD9, CD63, CD81, CD82, and 
CD151 in the predicted structure. Mouse INAM is a 40–55-kD 
protein with one N-glycosylation site and possesses four trans-
membrane motifs (Fig. 2, A and B). Western blotting analysis of 
INAM-transfected cells under nonreducing conditions showed 
no evidence of multimers (Fig. 2 B). The N-terminal and   
C-terminal regions of INAM are in the cytoplasm because anti-
Flag antibody did not detect C-terminal Flag-tagged INAM 
until cells were permeabilized (unpublished data).
Alignment of the predicted amino acid sequence of mouse 
INAM with that of the human orthologue revealed that the 
two INAMs shared a 71.7% amino acid identity. INAM is   
also called FAM26F (Table S1) and is in the FAM26 gene 
family (Bertram et al., 2008; Dreses-Werringloer et al., 2008). 
Sequence database searches identified six mouse INAM para-
logs. Although FAM26A/CALHM3, FAM26B/CALHM2, and 
FAM26C/CALHM1 are located on chromosome 19, FAM26D, 
FAM26E, and FAM26F/INAM are on chromosome 10.   
Only INAM was inducible with TLR agonists (unpublished 
data). All FAM26 family proteins have three or four trans-
membrane motifs predicted by the TMHMM Server (version 
2.0). Human CALHM1 has a conserved region (Q/R/N site) 
expression, fully activated NK cells (Fig. 1, C–E). Hence, in   
BDMCs, the TICAM-1–IRF-3 pathway, rather than other cyto-
kines, appears to induce cell surface molecules that mediate 
BMDC/NK contact and evoke NK cytotoxicity.
Identification of INAM
To identify the NK-activating cell surface molecule on BMDC, 
we performed microarray analysis on polyI:C-stimulated BMDC 
prepared from TICAM-1/ and WT mice. The results yielded 
nine TICAM-1–inducible molecules with transmembrane   
motifs (Table S1). Six were induced in an IRF-3–dependent   
manner, whereas three were still induced in IRF-3/ BMDC. 
The NK-activating ability of the products of these genes was in-
vestigated by introduction of lentivirus expression vector into 
IRF-3/ BMDC. BMDCs with the transduced genes were 
co-cultured with WT NK cells and polyI:C, and the NK- 
activating ability was evaluated by determining IFN- in the 
24-h co-culture. NK cells, but not the gene-transduced   
BMDCs, produced IFN- in the presence of polyI:C. Finally,   
we identified a tetraspanin-like molecule that satisfied our evalua-
tion criteria (IFN- and cytotoxicity) on the mDC-NK activa-
tion and named this molecule INAM. INAM clearly differed 
Figure 1.  IRF-3 in BMDC controls the capacity to activate NK cells in response to polyI:C. (A and B) WT or TICAM-1/ NK cells were co-cul-
tured with WT or TICAM-1/ BMDC in the presence of 10 µg/ml polyI:C for 24 h. NK cytotoxicity against B16D8 was determined by standard 51Cr release 
assay. E/T = 30. (C) WT NK cells were co-cultured with WT (, ), IRF-3/ (, ), or IRF-7/ (, ) BMDC in the presence (, , ) or absence (, 
, ) of 10 µg/ml polyI:C for 24 h. NK cytotoxicity against B16D8 was determined by standard 51Cr release assay at the indicated E/T ratio. (D) ELISA of 
IFN- in cultures of WT, TICAM-1/, IRF-3/, and IRF-7/ BMDC treated with 10 µg/ml polyI:C for 24 h. (E) Quantitative RT-PCR for IL-15 expression in 
BMDC stimulated with 10 µg/ml polyI:C. All data are means ± SD of duplicate or triplicate samples from one experiment that is representative of three.2678  INAM regulates NK activation | Ebihara et al.
for  TLR9,  barely 
induced INAM on 
BMDC.  High  in-
duction of INAM 
was  observed  in 
BMDC stimulated 
with LPS as well as 
polyI:C (Fig. 3 B), both of which can activate TICAM-1 to   
induce IRF-3 and IFN- activation (Fitzgerald et al., 2003;   
Oshiumi et al., 2003a,b; Yamamoto et al., 2003a,b). Because 
INAM is an IFN-inducible gene (Fig. 3 B), INAM induction 
may be amplified by type I IFNs.
We next examined whether INAM was localized to the 
cell surface membrane in BMDC. Immunofluorescence analy-
sis showed Flag-tagged INAM on the cell surface of BMDC. 
Plasma membrane expression of INAM was also confirmed 
by cell surface biotinylation (Fig. S3). Although the lentivirus 
inefficiently  infected  BMDC,  GFP  expression  levels  were 
similar in cells with control virus and those with INAM- 
expressing virus (Fig. 3 C). Transduction efficiency and ex-
pression from the lentivirus vector were adjusted using GFP 
expression (not depicted), and surface INAM expression was fur-
ther confirmed with BMDC, NK cells, and INAM-expressing 
BaF3 (INAM/BaF3) cells, in some cases using polyclonal anti-
body (Ab) against INAM (Fig. S4).
We then examined whether overexpressing INAM re-
sulted in signaling that directed BMDC maturation and pro-
duction of cytokines, including IFN- and IL-12p40, which 
are reported to enhance NK activity (Gerosa et al., 2002; 
Sivori et al., 2004; Lucas et al., 2007). The status of INAM-
transduced BMDC was assessed by CD86 expression and 
cytokine production, and no significant differences in these 
maturation markers were seen in BMDC overexpressing 
INAM  (Fig.  S5).  In  the  same  setting,  no  IL-12p70  was   
with ion channel properties at the C-terminal end of the   
second transmembrane motif that controls cytoplasmic Ca2+ 
levels (Dreses-Werringloer et al., 2008). However, the Q/R/N 
site was not found in INAM. CALHM1, 2, and 3 are highly 
expressed in brain. Quantitative RT-PCR revealed that INAM 
expression was high in spleen and LNs but low in thymus, 
liver, lung, and small intestine (Fig. 2 C), although expression 
of the other two FAM26 family members from chromosome 
10 was highest in brain (not depicted). All splenocytes examined 
(CD3+,  CD19+,  DX5+,  CD11b+,  CD11c+,  mDCs  [CD11c+ 
PDCA1], and plasmacytoid DCs [CD11cPDCA1+]) ex-
pressed INAM to some levels (Fig. 2 D). The INAM expression   
was inducible by polyI:C in LN cells (Fig. 2 E); the induction 
levels were more prominent in myeloid cells than in lympho-
cytes in the LNs (Fig. S2 A). NKp46+ and DX5+ NK cells also 
expressed INAM with low levels and the levels were mildly 
increased by polyI:C stimulation (Fig. S2 A and not depicted). 
Notably, only CD45+ cells expressed INAM, which excludes 
the participation of contaminating stromal cells in the INAM 
up-regulation (Fig. S2 B).
BMDC INAM activates NK cells
WT and IRF-7/ BMDCs induced high NK cytotoxicity in 
response to polyI:C, whereas TICAM-1/, IPS-1/, and   
IRF-3/ BMDC showed less NK activation (Fig. 1, B and C; 
and Fig. S1). INAM expression profile by polyI:C stimula-
tion was then examined using WT, IRF-3/, IRF-7/, and 
TICAM-1/ BMDCs. Stimulation with polyI:C induced 
INAM at normal levels in IRF-7/ BMDC but at decreased 
levels in IRF-3/ and  TICAM-1/ BMDC (Fig. 3 A).  The ex-
pression profiles of INAM in polyI:C-stimulated BMDC were 
in parallel with those inducing NK activation. BMDCs express a   
variety of TLRs (Iwasaki and Medzhitov, 2004), but other TLR 
ligands, Pam3CSK4 for TLR1/2, Malp2 for TLR2/6, and CpG 
Figure 2.  Sequence alignment of INAM 
and expression of INAM. (A) Sequence 
alignment of human and mouse INAM. Aster-
isks, identical residues; double dots, conserved 
substitutions; single dots, semiconserved 
substitutions; box, N-glycosylation site; un-
derline, transmembrane motif. (B) Immuno-
blot analysis of lysates of 293FT cells 
transfected with plasmid encoding Flag-
tagged INAM. PNGase, N-glycosidase. 2ME,  
2-mercaptoethanol. (C and D) Quantitative 
RT-PCR for INAM expression in mouse tissue 
(C) and spleen cells (D). CD3+, CD19+, DX5+, 
CD11b+, CD11c+, mDC (CD11c+PDCA1+), and 
plasmacytoid DC (pDC; CD11c+PDCA1+) cells 
were isolated from splenocytes by cell sorting. 
Data are expressed as copy number per 104 
copies of HPRT. Data shown are means ± SD 
of triplicate samples from one experiment 
that is representative of three. (E) Augmented 
INAM expression in LN cells after polyI:C 
stimulation. WT mice were i.p. injected with 
100 µg polyI:C or control buffer. After 24 h, 
inguinal, axillary, and mesenteric LN were 
harvested and RNA was extracted from the LN 
cells. The levels of the INAM mRNA were mea-
sured by real-time PCR. The results were con-
firmed in two additional experiments. Data 
represent mean ± SD.JEM VOL. 207, November 22, 2010 
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this NK activation was further enhanced by the 
addition  of  polyI:C  (Fig.  3,  D  and  E). Thus, 
polyI:C  may  also  work  for  NK  activation.   
Direct cell–cell contact with NK cells was re-
quired for INAM in IRF-3/ BMDC to func-
tion on enhancing NK activity (Fig. 3 F).
We further confirmed this issue using WT 
BMDC by shRNA gene silencing. We silenced 
the INAM gene in BMDC using the lentiviral 
vector pLenti-dest-IRES-hrGFP and monitored 
expression by GFP. Because transfection effi-
ciency was relatively high in this case compared 
with that shown in Fig. 3 C, the expression level 
of INAM had decreased by 75% in  WT BMDC 
compared with the nonsilenced control (Fig. 3 G 
and Fig. S6 A). Although the level of the endoge-
nous INAM protein was not very high, we confirmed that 
INAM protein was also decreased by shRNA with immuno-
blotting using anti-INAM pAb (Fig. S7 A). PolyI:C response of 
BMDC-inducible cytokines tested was not altered by INAM 
silencing in BMDC (Fig. S6 B). Yet this INAM RNA inter-
ference caused a significant decrease in NK cell IFN- produc-
tion after co-culture of the INAM knockdown BMDCs and 
WT NK cells with polyI:C (Fig. 3 H). Collectively, these re-
sults indicate that INAM is downstream of IRF-3 in BMDC 
and is involved in the activation of NK cells by BMDC.
detected by ELISA (unpublished data). In addition, polyI:C-
mediated NK activation occurred in BMDC expressing an 
INAM mutant lacking the cytoplasmic C-terminal region 
(193–327 aa; Fig. 4, A and B), excluding the participation of 
the cytoplasmic region in BMDC maturation signaling.
To investigate whether INAM could reconstitute NK- 
activating ability in IRF-3/ BMDC, we transduced INAM 
into IRF-3/ BMDC and incubated BMDC with NK cells. 
Overexpression of INAM in IRF-3/ BMDC induced NK 
IFN- production and NK cytotoxicity against B16D8, and 
Figure 3.  INAM in BMDC participates in DC- 
mediated NK activation. (A) Quantitative RT-PCR for INAM 
expression in WT, TICAM-1/, IRF-3/, and IRF-7/ 
BMDC stimulated with 10 µg/ml polyI:C. (B) Quantitative 
RT-PCR for INAM expression in WT BMDC stimulated by 
100 ng/ml LPS, 10 µg/ml polyI:C, 1 µg/ml Pam3, 100 nM 
Malp-2, 10 µg/ml CpG, and 2,000 IU/ml IFN- for 4 h.  
(C) BMDCs were transduced with Flag-tagged INAM- 
expressing lentivirus or control lentivirus. GFP expression in 
the BMDC was determined by flow cytometry, and subcel-
lular localization of INAM was examined by immuno-
fluorescence assay using anti-Flag mAb. Shaded peak, 
noninfected control; Blank peak, infected BMDC. Bar, 10 µm. 
(D) ELISA of IFN- induced by WT NK cells co-cultured  
with WT BMDC or IRF-3/ BMDC transfected with control 
lentivirus (CV) or INAM-expressing lentivirus (INAM) with/
without 10 µg/ml polyI:C. (E) Cytotoxicity against B16D8 by 
NK cells co-cultured with BMDC transfected with control 
or INAM-expressing lentivirus with/without 10 µg/ml  
polyI:C for 24 h. (F) ELISA of IFN- induced by WT NK cells 
co-cultured with IRF-3/ BMDC transfected with control 
lentivirus (CV) or INAM-expressing lentivirus (INAM) with 
10 µg/ml polyI:C. In some experiments, a transwell was 
inserted between the INAM-transduced BMDC and NK cells 
to separate the cells. (G) Quantitative RT-PCR for expres-
sion of INAM in BMDC transduced with INAM-shRNA 
(INAM) or scrambled shRNA (control) and cultured for  
48 h. (H) IFN- production by WT NK cells determined  
using ELISA after coculturing with control or the shRNA  
transfected-BMDC (INAM) and 10 µg/ml polyI:C for 24 h. 
All data shown are means ± SD of triplicate samples from 
one experiment that is representative of three.2680  INAM regulates NK activation | Ebihara et al.
extracellular functions. Thus, the function of INAM may not 
be confined to mDC, so we studied the function of INAM 
on NK cells. In NK cells, INAM was also inducible by polyI:C 
(Fig. 6 A and Fig. S2 A), and the induction of INAM was   
abrogated completely in IRF-3/ NK cells and moderately 
in TICAM1/ NK cells (Fig. 6 B). This suggests that polyI:C 
also acts on NK cells and induces INAM through IPS-1/
IRF-3 activation when NK cells are co-cultured with BMDC 
and polyI:C.
To investigate whether INAM induced in NK cells is as-
sociated with BMDC-mediated NK activation, we performed 
the  following  experiments  (Fig.  6  C).  INAM-transduced 
IRF-3/ BMDCs were incubated with polyI:C for 4 h, and 
then the aliquot was mixed with WT NK cells in the presence 
of polyI:C (Fig. 6 C, left two lanes). A moderate increase   
of IFN- was observed as in Fig. 3 D. In the remainder,   
Using an INAM-expressing stable BaF3 cell line (INAM/
BaF3), we tested the possibility that INAM is an activating li-
gand for NK cells. As a positive control, we produced a stable 
BaF3 cell line expressing Rae-1 (Fig. 5 A) which is a ligand 
for the NK-activating receptor NKG2D (Cerwenka et al., 
2000). Although Rae-1/BaF3 cells were easily damaged by 
IL-2–activated NK cells, INAM/BaF3 cells were not (Fig. 5 B). 
In this context, addition of IRF-3/ BMDC to this culture 
with BaF3 and NK cells led to slight augmentation of IFN- 
induction irrespective of the presence of INAM on BaF3 cells 
(Fig. 5 C), and 2-microglobulin/ BMDC barely affected the 
IFN- level (not depicted). These results suggest that an INAM-
containing molecular matrix, rather than INAM alone, acts 
toward NK cells. Alternatively, INAM may selectively func-
tion with specific mDC molecules to activate NK cells.
INAM on NK cells is required for efficient NK activation
mDCs were previously shown to be required for efficient NK 
activation in vivo and in vitro (Akazawa et al., 2007a). We 
found that INAM was minimally present in BMDCs and NK 
cells and that polyI:C acts on both (Figs. S2 A; and Fig 3,   
D and E). Tetraspanin-like molecules tend to work as scaffolds 
for heteromolecular complexes that contain molecules function-
ing in a cis- or trans-adhesion manner to exert intercellular or 
Figure 4.  Role of the cytoplasmic tail of INAM. (A) The C-terminal 
region of INAM was not required for BMDC-mediated NK activation. ELISA 
of IFN- by WT NK cells co-cultured with IRF-3/ BMDCs transfected 
with control lentivirus (CV) or a lentivirus expressing intact INAM or a 
mutant INAM lacking the C-terminus (C-del INAM) with/without 10 µg/ml 
polyI:C. Data shown are means ± SD of triplicate samples from one experi-
ment representative of three. (B) The cytoplasmic tail of INAM is indispens-
able for NK IFN- induction. INAM or C-del INAM (A) was expressed on 
IRF-3/ NK cells. The INAM (or C-del INAM)-expressing IRF-3/ NK cells 
were incubated with or without WT BMDC for 24 h. IFN- levels in the 
supernatants were determined by ELISA. One representative result out of 
several similar experiments is shown. Data represent mean ± SD.
Figure 5.  INAM is not an NK-activating ligand. (A) Flow cytometry 
for Rae-1 and Flag-tagged INAM in stable BaF3 lines. Shaded peak, un-
transfected control BaF3 staining with anti–pan-Rae-1 Ab or anti-Flag 
M2 antibody; open peak, stable Rae-1/BaF3 or stable Flag-tagged INAM/
BaF3 staining with anti–pan-Rae-1 antibody or anti-Flag M2 antibody.  
(B) Cytotoxicity against control BaF3, Rae-1/BaF3, and INAM/BaF3 by NK 
cells treated with 1,000 IU/ml IL-2 for 3 d. Data shown are means ± SD of 
triplicate samples from one experiment representative of three. (C) NK 
activation is augmented by coexistent BMDC irrespective of INAM expres-
sion. NK cells were cultured with 1,000 IU/ml IL-2 for 3 d. 2 × 105 NK cells, 
105 BaF3 cells, and 105 IRF-3/ BMDCs were co-cultured in 200 µl/well 
and IFN- in the supernatants were measured by ELISA. Data show one of 
two similar experimental results. Data represent mean ± SD.JEM VOL. 207, November 22, 2010 
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on BMDC and NK cells are essential for BMDC-mediated 
NK activation.
We next checked the function of the C-terminal stretch 
of INAM in NK activation. Although intact INAM works in 
NK cells to produce IFN- in response to BMDC (Fig. 6 F), 
introduction of C-del INAM into IRF-3/ NK cells did 
not result in high induction of IFN- in response to BMDC 
(Fig. 4 C). Thus, INAM participates in NK activation through 
its  cytoplasmic  regions,  which  has  no  significant  role  in 
BMDC for NK activation.
Anti-tumor NK activation via INAM-expressing BMDCs in vivo
mDC-mediated NK activation induces anti-tumor NK cells, 
which cause regression of NK-sensitive tumors (Kalinski et al., 
2005; Akazawa et al., 2007a). We tested the in vivo function of 
INAM-expressing BMDC using B16D8 tumor-bearing mice. 
BMDCs were used 24 h after transfection with either INAM/
pLenti-IRES-hrGFP or control pLenti-IRES-hrGFP and   
injected twice a week s.c. around a preexisting tumor in   
tumor-implanted mice, beginning 11–13 d after tumor chal-
lenge. INAM-expressing BMDC significantly retarded tumor 
growth (Fig. 7 A). Tumor retardation was abrogated by depletion 
of NK1.1-positive cells (Fig. 7 B). Thus, INAM expression on 
BMDC contributed to anti-tumor NK activation in vivo.
When  the  control  or  INAM-expressing  IRF-3/  
BMDCs were co-cultured with WT NK cells in vitro, there was 
no induction of the mRNA of TRAIL and granzyme B in 
we washed polyI:C out and cultured the cells with WT NK 
cells  (Fig.  6  C,  right  two  lanes).  Under  these  conditions,   
in  which  polyI:C  acted  not  on  NK  cells  but  only  on 
BMDC, little NK activation was observed (Fig. 6 C). Fur-
thermore, IRF-3/ NK cells produced little IFN- when co- 
cultured with WT BMDC and polyI:C (Fig. 6 D). INAM- 
overexpressing IRF-3/ BMDC required IRF-3 in NK cells 
for  efficient  BMDC-mediated  production  of  IFN-  from 
NK cells (Fig. 6 D). We next transduced INAM into IRF-3/ 
NK cells using a lentivirus (INAM/pLenti-IRES-hrGFP) to 
reconstitute NK IFN-–producing activity. After many trials 
with various setting conditions, we found that 15% of the 
DX5+ NK cell population was both GFP-positive and stained 
with  anti-FLAG  mAb  when  treated  with  high  doses  of 
INAM-expressing lentivirus vector (Fig. S7 B). When IRF-3/ 
NK  cells  were  infected  with  smaller  amounts  of  INAM- 
expressing lentiviral vector and cultured for 3 d with high con-
centrations of IL-2 (500 IU/ml), slight but significant GFP 
expression  was  confirmed  by  FACS  (Fig.  6  E). Then,  the 
INAM-transduced  IRF-3/  NK  cells  were  co-cultured 
with WT BMDC. The IRF-3/ NK cells with INAM ex-
pression secreted IFN- at significantly higher levels than 
controls in the presence of WT BMDC (Fig. 6 F). These data 
indicate that INAM is induced by polyI:C through IRF-3 
activation, not only in BMDCs but also in NK cells, and   
that INAM on NK cells synergistically works with INAM   
on BMDC for efficient NK cell activation. Both INAMs   
Figure 6.  INAM on NK cells contributes to efficient NK activation mediated by mDC. (A and B) Quantitative RT-PCR for INAM expression in WT, 
TICAM1/, or IRF-3/ NK cells stimulated with 50 µg/ml polyI:C. Data shown are means of duplicate or triplicate samples from one experiment that is 
representative of three. (C) IRF-3/ BMDCs were transfected with control lentivirus (CV) or INAM-expressing lentivirus (INAM) before treatment with  
10 µg/ml polyI:C for 4 h. BMDCs in some wells were washed to remove polyI:C before WT NK cells were added (Wash). IFN- production by NK cells was 
determined by ELISA after 24 h of culture. Data show one of two similar experimental results. (D) ELISA of IFN- in co-culture of WT or IRF-3/ NK cells 
and WT BMDC with/without 10 µg/ml polyI:C. (E and F) NK cells were transfected with control lentivirus or INAM-expressing lentivirus and cultured with 
500 IU/ml IL-2 for 3 d. After determining transfection efficiency by GFP intensity using flow cytometry, cells were cultured with/without BMDC for 24 h 
and IFN- production in the supernatant determined by ELISA. Shaded peak, noninfected control; open peak, infected BMDC. All data are means ± SD of 
triplicate samples from one experiment that is representative of three.2682  INAM regulates NK activation | Ebihara et al.
(Kalinski et al., 2005; Akazawa et al., 2007a,b). Systemic ad-
ministration of polyI:C unequivocally results in activation of 
peripheral NK cells (Lee et al., 1990; Sivori et al., 2004; Akazawa 
et al., 2007a). Although the molecular mechanism by which 
mDCs prime NK cells was still unclear, the TICAM-1 path-
way and IPS-1 pathway have been reported to participate in 
polyI:C-mediated mDC maturation that drives NK activa-
tion (Akazawa et al., 2007a; McCartney et al., 2009; Miyake 
et al., 2009). We have shown in an earlier study that mDCs 
disrupted in the TLR3–TICAM-1 pathway abrogate NK cell 
activation (Akazawa et al., 2007a,b). In TICAM-1/ mice, 
NK-sensitive implant tumors grew as well as those in WT 
mice depleted of NK cells (Akazawa et al., 2007a). mDCs   
gain high anti-tumor potential against B16D8 implant tumors 
through lentiviral transfer of TICAM-1, which is attributable 
to NK activation (Akazawa et al., 2007a). We further showed 
that TICAM-1 is a critical molecule for mDC to induce NK cell 
IFN-, as well as IPS-1, and participates in driving NK cyto-
toxicity to a lesser extent than IPS-1. In this paper, we clari-
fied a molecular mechanism by which mDCs immediately 
promote NK cell functions in vitro and in vivo.
Our findings showed that IRF-3 is the transcription factor 
that is downstream of TICAM-1 responsible for maturing mDC 
to an NK-activating phenotype. We discovered that INAM, a 
membrane-associated protein, is up-regulated on the surface of 
mDC by polyI:C stimulation and activates NK cells via cell–cell 
contact. Furthermore, we found that NK cells also express INAM 
on their cell surface after polyI:C stimulation. mDC–NK activa-
tion  by  polyI:C  can  be  reproduced  with  INAM-transduced 
mDC and NK cells, and adoptive transfer experiments show that 
INAM-overexpressing  mDC  may  have  therapeutic  potential 
against MHC-low melanoma cells in an NK-dependent manner. 
These functional properties of INAM-expressing mDC fit the 
model of mDC priming NK activation. Ultimately, INAM ap-
pears to be the key molecule in the previously reported mecha-
nism of mDC–NK contact activation.
After the submission of this manuscript, two papers were 
published that found that the MDA5–IPS-1 pathway in mDC 
is more important for driving NK activation, particularly in 
vivo (McCartney et al., 2009; Miyake et al., 2009). Our data 
also support this point using the IPS-1/ mice we estab-
lished (Fig. S1). However, polyI:C, when i.v. administered into 
mice, may stimulate other systemic cells in addition to CD8+ 
mDC in vivo (McCartney et al., 2009). The difference among 
the two (McCartney et al., 2009; Miyake et al., 2009) and this 
study may be attributed to the setting conditions, which are 
not always comparable. Moreover, it remains to be settled 
whether TICAM-1 and IPS-1 take the same INAM complex 
as a common NK activator in mature mDC and whether 
TLR3 (or MDA5) KO is equivalent to TICAM-1 (or IPS-1) 
KO in the mDC–NK activation model. In either case, how-
ever, up-regulation of mDC TICAM-1–mediated NK cyto-
toxicity and IFN- induction are feasible with polyI:C under 
three different conditions (Akazawa et al., 2007a; McCartney 
et al., 2009; Miyake et al., 2009). Our results infer that INAM 
participates in at least these mDC–NK interactions.
NK cells (Fig. 8 A). TRAIL and granzyme B were induced in 
NK  cells  by  the  addition  of  polyI:C  to  the  mixture,  and 
INAM expression in BMDC up-regulated mRNA levels of 
TRAIL and granzyme B (Fig. 8 A). In vivo administration 
studies were performed with polyI:C-treated WT BMDC or 
INAM-expressing IRF-3/ BMDC to test their ability to 
up-regulate the mRNA levels of TRAIL and granzyme B in 
NK cells in draining LN (Fig. 8 B). INAM-expressing IRF-3/ 
BMDC showed comparable abilities to up-regulate the kill-
ing effectors with polyI:C-treated BMDC (Fig. 8 B). Collec-
tively,  INAM  has  therapeutic  potential  for  NK-sensitive 
tumors by activating NK cells.
DISCUSSION
Previous  studies  demonstrated  that  mDC–NK  interaction 
leads to direct NK activation and damages NK target cells   
in vitro (Gerosa et al., 2002; Sivori et al., 2004; Akazawa et al., 
2007a; Lucas et al., 2007). In addition, mDCs initiate NK 
cell–mediated innate anti-tumor immune responses in vivo 
Figure 7.  INAM on BMDC retarded B16D8 tumor growth in an NK-
dependent manner. (A) Tumor volume after DC therapy using BMDC ex-
pressing INAM. B16D8 cells were s.c. injected into C57BL/6 mice and, 11–13 d  
later, medium only () or BMDC (106/mouse) transfected with control lenti-
virus () or those with INAM-expressing lentivirus () were administered  
s.c. near the tumor at the time indicated by the open arrow. *, P = 0.043. Data 
represent mean ± SD. (B) Abrogation of INAM-dependent tumor regression 
by administration of NK1.1 Ab. For depletion of NK cells, antiNK1.1 mAb was 
injected i.p. 1 d before treatment of BMDC (arrowheads). Tumor volume in 
every mouse group was sequentially monitored. Data represent mean ± SD 
(n = 3) and are representative of two experiments. Statistical analyses were 
made with the Student’s t test. **, P = 0.017.JEM VOL. 207, November 22, 2010 
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in high induction 
of  IFN-  in  re-
sponse to BMDC 
(Fig.  4  C).  To-
gether  with  the 
data on INAM ex-
pression in BMDC, this infers that the INAM cytoplasmic   
region signals for NK activation in NK cells. The one-way role 
of the cytoplasmic tail in NK activation will be an issue for fur-
ther analysis.
In this study, IL-15 was found to be up-regulated by polyI:C 
in BMDC. The remaining NK activity in the resting popu-
lation of NK cells co-cultured with TICAM-1/ BMDC 
and polyI:C (Fig. 1 B) suggests that IL-15 has some effect in 
our system, and other studies suggest this as well (Ohteki et al., 
2006; Brilot et al., 2007; Lucas et al., 2007; Huntington et al., 
2009). However, we did not observe decreased IL-15 expres-
sion in the TICAM-1/ BMDC that could not activate NK 
cells (Fig. 1 E). Several molecules, such as B7-H6/NKp30 
(Brandt et al., 2009), CD48/2B4 (Kubin et al., 1999), and 
NKG2D ligands/NKG2D (Cerwenka et al., 2000), have been 
identified as ligand/receptor molecules in mDC–NK recip-
rocal activation by in vitro co-culture. In in vitro co-culture 
systems (Fig. S1), the IPS-1 pathway in BMDC has a pivotal 
role in not only type I IFN but also IL-15 induction. INAM 
identified in this paper serves a unique function in the in vivo 
induction of NK activation and may offer a tool to investigate 
the reported mDC-mediated NK activation.
Rae-1 was reported as a molecule with MHC-like struc-
ture (Zou et al., 1996) and later identified as a mouse NKG2D 
ligand (Cerwenka et al., 2000). Although Rae-1 is a GPI- 
anchored protein with no cytoplasmic sequences (Nomura et al., 
1996), it can act as an NK-activating ligand (Cerwenka et al., 
2000, 2001; Masuda et al., 2002). Mouse BaF3 cells become 
NK-sensitive after forced expression of Rae-1 (Masuda et al., 
2002). Actually, mouse macrophages induce Rae-1 expression 
in response to TLR stimuli (Hamerman et al., 2004). In contrast, 
PolyI:C activates IRF-3 through the two pathways involv-
ing the adaptors IPS-1 and TICAM-1 (Yoneyama et al., 2004; 
Kato et al., 2006; Matsumoto and Seya, 2008). The two path-
ways  share  the  complex  of  IRF-3–activating  kinase,  NAP1, 
IKK-, and TBK1 that is downstream of adaptors (Sasai et al., 
2006). Nevertheless, these pathways are capable of inducing sev-
eral genes unique to each adaptor. Although IFN- production 
by in vivo administration of polyI:C is largely dependent on the 
IPS-1 pathway, IL-12p40 is mainly produced by the TICAM-1 
pathway (Kato et al., 2006). Therefore, it is not surprising that 
INAM induction is predominant in the TICAM-1 pathway   
in polyI:C-stimulated BMDC (Fig. 3 A). What happens in   
IRF-7/ BMDCs in terms of INAM induction and what 
mechanism  sustains  BMDC  IPS-1–mediated  or  MyD88- 
mediated activation of NK cells (Azuma et al., 2010) will be   
issues to be elucidated in the future.
Although IRF-3–regulated cell surface INAMs are re-
quired for efficient interaction between BMDC and NK cells, 
the mechanism by which forced expression of INAM causes 
signaling for BMDC maturation is still unknown. Although 
the NK-activating capacity of BMDCs is usually linked to 
their maturation, neither cytokines in NK activation, includ-
ing IFN- and IL-12p70, nor costimulators, such as CD40 
and CD86, were specifically induced in mDC by INAM ex-
pression (Fig. S5). INAM has a C-terminal cytoplasmic stretch 
(Fig. 4 A), and we tested the function of this region by a deletion 
mutant (C-del INAM). This region in BMDC barely partici-
pates in driving NK activation because no decrease of IFN- 
induction by NK cells was observed with IRF-3/ BMDC 
supplemented  with  C-del  INAM  compared  with  control 
INAM. Thus far, no significant signal alteration has been de-
tected in BMDC supplemented with INAM by lentivirus.
In contrast, INAM-transduced IRF-3/ NK cells produced 
IFN- in concert with BMDCs like WT NK cells (Fig. 6 F). So 
far we have no evidence suggesting that this kind of INAM 
overexpression is actually occurring in vivo. However, intro-
duction of C-del INAM into IRF-3/ NK cells did not result 
Figure 8.  INAM-mediated induction of 
TRAIL and granzyme B in BMDC. (A) In vitro 
induction of TRAIL (Tnfsf10) and granzyme B 
(Gzmb) mRNA by INAM-expressing BMDC. 
BMDCs (IRF-3/) were infected with INAM-
expressing virus or CV as in Fig. S4. After 24 h, 
the BMDCs (IRF-3/) were incubated with WT 
NK cells at DC/NK = 1:2. 8 h later, DX5+ cells 
were collected by FACS sorting and their RNA 
was extracted to determine the mRNA levels of 
the indicated genes. A representative result of 
three similar experiments are shown. (B) In vivo 
induction of TRAIL and granzyme B mRNA  
by INAM-expressing BMDC. WT BMDCs were 
stimulated with 10 µg/ml polyI:C or medium 
only. IRF-3/ BMDCs were infected with CV or 
INAM-expressing vector. These BMDCs were 
allowed to stand for 24 h and then 5 × 105 
cells were injected into footpads of WT mice. 
After 48 h, DX5+ cells were collected from the 
inguinal LN by FACS sorting. RNA of the cells 
was extracted and the levels of the indicated 
mRNA were determined by real time PCR. Data 
show one of two experiments with similar 
results. Data in A and B represent mean ± SD.2684  INAM regulates NK activation | Ebihara et al.
control (shCont/pLDIG). We used a gene-expression kit, Lentiviral system 
(Invitrogen), as previously described (Akazawa et al., 2007a). Four plasmids 
(one of the pLenti vectors, pLP1, pLP2, and pLP/VSVG) were transfected 
into 293 FT packaging cells, and the viral particles for transfection were pre-
pared according to the manufacturer’s protocol. The 100× concentrated virus 
particles were produced after centrifugation of 8,000 g at 4°C for 16 h. Len-
tivirus produced by pLenti-IRES-hrGFP and pLDIBG could be tittered by 
GFP expression using flow cytometry. Because the lentivirus vector pLenti-
IRES-hrGFP has the IRES-GFP region, we prepared negative control virus 
by pLenti-IRES-hrGFP without construct. Infection efficiency for BMDC 
was high with the control vector compared with the INAM-expressing   
lentivector (Fig. S6 A).
Real-time PCR. BMDCs were harvested after 4 h of stimulation by 100 ng/ml 
LPS, 50 µg/ml polyI:C, 1 µg/ml Pam3CSK4 (Pam3), 100 nM mycoplasmal 
macrophage-activating lipopeptide-2 (Malp-2), 10 µg/ml CpG, and 2,000 
IU/ml IFN- (Ebihara et al., 2007). Mouse tissues (heart, stomach, small intes-
tine, large intestine, lung, brain, muscle, liver, kidney, thymus, and spleen) were 
collected from C57BL/6. Splenocytes were stained with CD3-PE, CD19-
PE, DX5-PE, CD11b-PE, CD11c-FITC, and PDCA1-PE (eBioscience) and 
sorted by FACSAria (BD). Purity was >98% in each population. For RNA 
extraction, we used the RNeasy kit (Invitrogen). After removal of genomic 
DNA by treatment with DNase, randomly primed cDNA strands were gen-
erated with Moloney mouse leukemia virus reverse transcription (Promega).   
RNA  expression  was  quantified  by  quantitative  RT-PCR  with  gene- 
specific primers (IL-15 forward, 5-TTAACTGAGGCTGGCATTCATG-3; 
IL-15 reverse, 5-ACCTACACTGACACAGCCCAAA-3; INAM forward, 
5-CAACTGCAATGCCACGCTA-3;  INAM  reverse,  5-TCCAACC-
GAACACCTGAGACT-3;  -actin  forward,  5-TTTGCAGCTCCTTC-
GTTGC-3;  -actin  reverse,  5-TCGTCATCCATGGCGAACT-3;  HPRT 
forward, 5-GTTGGATACAGGCCAGACTTTGTTG-3; and HPRT re-
verse, 5-GAAGGGTAGGCTGGCCTATAGGCT-3) and values were nor-
malized to the expression of -actin mRNA or HPRT mRNA.
Other primers for PCR were designed using Primer Express software   
(Applied Biosystems) for another experiment. The following primers   
were used for PCR: -actin forward, 5-CCTGGCACCCAGCACAAT-3  
and reverse, 5-GCCGATCCACACGGAGTACT-3; granzyme B forward,   
5-TCCTGCTACTGCTGACCTTGTC-3 and reverse, 5-ATGATCTC-
CCCTGCCTTTGTC-3;  IFN-4  forward,  5-CTGCTGGCTGTGAG-
GACATACT-3 and reverse, 5-AGGCACAGAGGCTGTGTTTCTT-3; 
TRAIL  (Tnfsf10)  forward,  5-CTTCACCAACGAGATGAAGCAG-3 
and  reverse,  5-TCCGTCTTTGAGAAGCAAGCTA-3;  and  IL-12p40 
(Il12b),  forward,  5-AATGTCTGCGTGCAAGCTCA-3  and  reverse, 
5-ATGCCCACTTGCTGCATGA-3.
Anti-INAM pAb. C-terminal INAM (cINAM; 191–314 aa) was subcloned 
between the NdeI and Sal1 sites of pColdI vector (Takara Bio Inc.). 6× His-
tagged cINAM protein was expressed in BL21 by manufacturer’s methods. The 
cells were sonicated in 20 mM Tris-HCl, 150 mM NaCL, 1 mM PMSF, and 7 M 
Urea, pH 7.4, on ice. Expression products of cINAM were purified using the 
HisTrap HP kit (GE Healthcare). The extracted proteins were refolded by step-
wise dialysis against decreasing amounts of urea. Rabbit anti-cINAM polyclonal 
Ab was produced with the cINAM proteins by standard protocol. IgG was puri-
fied by precipitation with 33% ammonium sulfate, dialyzed against PBS.
Surface labeling with biotin. Biotinylation of cell surface proteins was per-
formed according to the reported method (Tsuji et al., 2001). In brief, 108 cells 
were suspended in 1 ml Hepes-buffered saline (HBS), pH 8.5, and incubated 
with 10 ml of 10 mg/ml NHS-sulfobiotin (Vector Laboratories) for 1 h at room 
temperature. Cells were washed in HBS three times and then solubilized with   
lysis buffer containing 1% NP-40, pH 7.4. The cell lysate was immunoprecipi-
tated with avidin-labeled Abs as described previously (Tsuji et al., 2001).
Immunoblot analysis. Lysates were harvested 24 h after transfection of   
Flag-tagged INAM/pEFBOS into 293FT cells and treated with N-glycosidase F 
INAM-expressing stable BaF3 cell lines (INAM/BaF3) did 
not reveal a function as an NK cell–activating ligand. NK cell 
cytotoxicity is directed against Rae-1/BaF3 cells but not 
against INAM/BaF3 cells (Fig. 5). Therefore, INAM does not 
represent a typical NK cell–activating ligand. For NK activa-
tion, INAM on BMDC appears to require other molecules 
that are expressed in BMDC but not in BaF3.
INAM has four transmembrane regions, similar to the cell 
adhesion tetraspanins, which may support cell–cell contact 
(Levy and Shoham, 2005). Tetraspanins provide a scaffold that 
facilitates complex formation with associated proteins. INAM 
on BMDC and NK cells may use cell–cell interaction to as-
semble in a synaptic formation to activate NK cells. Because 
the protein constituents of the tetraspanin complexes are cell 
specific, we are interested in finding partners for INAM that 
might participate in efficient BMDC–NK interaction. TLR-
inducible cell–cell contact may occur through INAM in an 
immune cell–specific manner. Gene disruption of this INAM 
will facilitate clarifying this issue. The identification of INAM 
defines a novel pathway in mDC–NK reciprocal interaction. 
This study will lead to further research on the molecules that 
form complexes on BMDC and NK cells to facilitate BMDC–
NK interaction.
MATERIALS AND METHODS
Mice. All mice were backcrossed with C57BL/6 mice more then seven 
times before use. TICAM-1/ (Akazawa et al., 2007a) and IPS-1/ mice 
were generated in our laboratory. IRF-3/ (Sato et al., 2000) and IRF-7/ 
mice (Honda et al., 2005) were provided by T. Taniguchi (University of   
Tokyo, Tokyo, Japan). All mice were maintained under specific pathogen-free 
conditions in the animal facility of the Hokkaido University Graduate School 
of Medicine. Animal experiments protocols and guidelines were approved by 
the Animal Safety Center, Hokkaido University, Japan.
Cells. The B16D8 cell line was established in our laboratory as a subline of 
B16 melanoma (Tanaka et al., 1988). This subline was characterized by its   
low or virtually no metastatic properties when injected s.c. into syngeneic 
C57BL/6 mice. B16D8 was cultured in RPMI 1640/10% FCS. The mouse 
B cell line BaF3 was obtained from American Type Culture Collection and 
cultured in RPMI 1640/10% FCS/2 µM 2ME/5 ng/ml IL-3. Mouse NK 
cells (DX5+ cell) were positively isolated with MACS Beads (Miltenyi   
Biotec). Mouse BMDCs were prepared as previously reported (Akazawa   
et al., 2007a).
For purification of cells from spleen or LN, these tissues were treated 
with 400 IU MandleU/ml collagenase D (Roche) at 37°C for 25 min in 
HBSS (Sigma-Aldrich). Then EDTA was added, and the cell suspension was 
incubated for an additional 5 min at 37°C. After removal of RBC with ACK 
lysis buffer, splenocytes and LN cells were stained with CD45-FITC, CD3-
PE, CD19-PE, DX5-PE, CD11b-FITC (eBioscience), and CD11c-FITC 
(BioLegend) and sorted by a FACSAria II (BD). The purity of sorted cells 
were >96%.
Construction and expression. Mouse INAM cDNA (A630077B13Rik) 
was obtained from RIKEN and placed into expression vector pEFBOS and 
pLenti-IRES-hrGFP,  both  of  which  provide  the  specialized  components 
needed for expression of a recombinant C-terminal FLAG fusion (Akazawa 
et al., 2007a). For construction of shRNA-expressing lentivirus vector, The 
ClaI–XhoI fragment of pLenti6-blockit-dest (Invitrogen) was inserted into 
pLenti-IRES-hrGFP at the site of ClaI and XhoI. This vector was named 
pLenti-dest-IRES-hrGFP (pLDIG). INAM sequence 5-CTTCTCTCCG-
GTTAGTTATCT-3  was  targeted  for  INAM  knockdown  (shINAM/
pLDIG) and 5-AGTCTGACATACTTATACTTA-3 was used for negative JEM VOL. 207, November 22, 2010 
Article
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Online supplemental material. TICAM-1–inducible genes encoding pu-
tative membrane proteins relevant for this study are summarized in Table S1.   
Fig. S1 shows KO mice results suggesting that both IPS-1 and TICAM-1   
in BMDC participate in polyI:C-driven NK activation. Data presented in   
Fig. S2 characterizes the in vivo polyI:C response of INAM in LN cells.   
Figs. S3 and S4 demonstrate the properties of surface-expressed INAM ana-
lyzed by immunoprecipitation/blotting and confocal microscopy, respectively. 
Fig. S5 mentions the cytokine expression and maturation profiles of INAM- 
overexpressing BMDC. Fig. S6 shows the effect of gene silencing of INAM 
on the polyI:C-mediated cytokine-inducing profile in BMDC. Two pieces   
of data presented in Fig. S7 confirm the presence of the INAM protein in INAM 
lentivirus-transduced BMDCs and NK cells. Online supplemental material is 
available at http://www.jem.org/cgi/content/full/jem.20091573/DC1.
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